KCT0004541招募中未知
Open-Label, Single arm, Phase II trial to evaluate efficacy and safety of Nivolumab as maintenance therapy following Platinum-based chemotherapy in non-small cell lung cancer patients after tyrosine kinase Inhibitor therapy
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 0No Limit（—）
- 性别
- All
入选标准
- •1. Sex: Male or female
- •2. Age (at the time of informed consent): 18 years and older
- •3. Patients with histologically- or cytologically-confirmed advanced, metastatic, or recurrent non-small cell lung cancer [according to edition 8 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology]
- •4. Patients whose disease had progressed after one or two TKIs treatment with targetable driver mutation including EGFR mutation, ALK fusion, and ROS1 rearrangement.
- •(Allowed TKIs must be approved by the local health authority, including but not limited to gefitinib, erlotinib, afatinib, dacomitinib, osimertinib, alectinib, brigatinib, crizotinib and ceritinib)
- •5. Patients who did not shown disease progression at the time of finishing four cycles of Platinum-based chemotherapy after TKI therapy failure
- •6. Patients who have at least 1 measurable lesion per the RECIST Guideline Ver. 1.1. If patients only have lesions that were previously treated with radiation, the lesion should be limited to one with confirmed aggravation by imaging after radiation.
- •7. Eastern Cooperative Oncology Group (ECOG) Performance Status Score 0 or 1
- •8. Patients with a life expectancy of at least 3 months
- •9. Patients whose latest laboratory data meet the below criteria. Of note, laboratory data will not be valid if the patient has received a granulocyte colony-stimulating factor (G-CSF) or blood transfusion within 14 days before testing.
- •White blood cells = 2 x 103/µL and Absolute neutrophil count (ANC) = 1,500/µL
- •Platelets = 100 x 103/µL
- •Hemoglobin = 9.0 g/dL
- •AST (SGOT) and ALT (SGPT) = 3.0-fold the upper limit of normal (ULN) of the study site (or =5.0-fold the ULN of the study site in patients with liver metastases)
- •Total bilirubin = 1.5-fold the ULN of the study site
- •Creatinine = 1.5-fold the ULN of the study site or creatinine clearance (either the measured or estimated value using the Cockcroft-Gault equation) > 45 mL/min
- •10. Women of childbearing potential (including women with chemical menopause or no menstruation for other medical reasons) #1 must agree to use contraception#2 from the time of informed consent until 5 months or more after the last dose of the investigational product. Also, women must agree not to breastfeed from the time of informed consent until 5 months or more after the last dose of the investigational product.
- •11. Men must agree to use contraception#2 from the start of study treatment until 7 months or more after the last dose of the investigational product.
- •#1. Women of childbearing potential are defined as all women after the onset of menstruation who are not postmenopausal and have not been surgically sterilized (e.g., hysterectomy, bilateral tubal ligation, bilateral oophorectomy). Postmenopause is defined as amenorrhea for =12 consecutive months without specific reasons. Women using oral contraceptives, intrauterine devices, or mechanical contraception such as contraceptive barriers are regarded as having childbearing potential.
- •#2. The subject must consent to use any two of the following methods of contraception: vasectomy or condom for patients who are male or female subject’s partner and tubal ligation, contraceptive diaphragm, intrauterine device, spermicide, or oral contraceptive for patients who are female or male subject’s partner.
排除标准
- •1. Patients with known SCLC transformation
- •2. Patients with multiple primary cancers (with the exception of completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer, or any other cancer that has not recurred for at least 5 years)
- •3. Patients with residual adverse effects of prior therapy or effects of surgery that would affect the safety evaluation of the investigational product in the opinion of the investigator
- •4. Patients with current or past history of severe hypersensitivity to any other antibody products
- •5. Patients with concurrent autoimmune disease or history of chronic or recurrent autoimmune disease (17.3 List of autoimmune disease). Patients with controlled asthma in the opinion of the investigator may be enrolled.
- •6. Patients with a current or past history of interstitial lung disease diagnosed based on imaging or clinical findings. Patients with radiation pneumonitis may be enrolled if the radiation pneumonitis has been confirmed as stable (beyond acute phase) without any concerns about recurrence.
- •7. Patients with concurrent diverticulitis or symptomatic gastrointestinal ulcerative disease
- •8. Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment. Patients may be enrolled if the metastasis is asymptomatic and requires no treatment.
- •9. Patients with pericardial fluid, pleural effusion, or ascites requiring treatment
- •10. Patients with uncontrollable, tumor-related pain
- •11. Patients who have experienced a transient ischemic attack, cerebrovascular accident, thrombosis, or thromboembolism (pulmonary arterial embolism or deep vein thrombosis) within 180 days before enrollment
- •12. Patients with a history of uncontrollable or significant cardiovascular disease meeting any of the following criteria:
- •- Myocardial infarction within 180 days before enrollment
- •- Uncontrollable angina pectoris within 180 days before enrollment
- •- New York Heart Association (NYHA) Class III or IV congestive heart failure
- •- Uncontrollable hypertension despite appropriate treatment (e.g., systolic blood pressure =150 mmHg or diastolic blood pressure = 90 mmHg lasting 24 hours or more)
- •- Arrhythmia requiring treatment
- •13. Patients receiving or requiring anticoagulant therapy for a disease. Patients receiving antiplatelet therapy including low-dose aspirin may be enrolled.
- •14. Patients with uncontrollable diabetes mellitus
- •15. Patients with systemic infections requiring treatment
- •16. Patients who have received systemic corticosteroids [except for temporary use (e.g., for examination or prophylaxis of allergic reactions) or use for pneumonitis treatment] or immunosuppressants within 28 days before enrollment
- •17. Patients who have received chemotherapy within 14 days before enrollment
- •18. Patients who have undergone surgical adhesion of the pleura or pericardium within 28 days before enrollment
- •19. Patients who have undergone surgery under general anesthesia within 28 days before enrollment
- •20. Patients who have undergone surgery involving local or topical anesthesia within 14 days before enrollment
- •21. Patients who have received radiotherapy within 14 days before enrollment, or radiotherapy to bone metastases within 14 days before enrollment
- •22. Patients who have undergone CyberKnife or Gamma knife treatment 14 or fewer days before enrollment
- •23. Patients who have received any radiopharmaceuticals (excep
研究者
相似试验
进行中（未招募）
1 期
Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of ageEUCTR2011-000987-92-DEPharming Technologies B.V.20
进行中（未招募）
1 期
Safety of Ruconest in children with HAEAttacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.MedDRA version: 18.1Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000987-92-HUPharming Technologies B.V.20
进行中（未招募）
1 期
Safety of Ruconest in children with HAEAttacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.MedDRA version: 17.0Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000987-92-SKPharming Technologies B.V.20
进行中（未招募）
1 期
Safety of Ruconest in children with HAEAttacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.MedDRA version: 18.1Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000987-92-CZPharming Technologies B.V.20
进行中（未招募）
1 期
Open-label study to evaluate the safety, and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of ageHereditary angioedema (HAE). Hereditary angioedema is characterized by angioedema localized and recurrent caused by by uncontrolled activation of the Complement systems due to congenital deficiency of Functional C1 inhibitor (C1INH). Reports in Medical the literature suggests that C1INH replacement therapy with human plasma-derived represents a safe and effective acute attacks of HAMedDRA version: 14.1Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000987-92-ITPHARMING TECHNOLOGIES B.V.20